Welcome to our dedicated page for CME GROUP SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CME GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CME GROUP's regulatory disclosures and financial reporting.
Form 144 notice for CME Group, Inc. (CME) shows a proposed sale of 11,896 common shares valued at approximately $3,229,452.32, to be executed through Morgan Stanley Smith Barney on NASDAQ on 08/26/2025. The filer acquired the shares as performance shares (2,283 shares, acquired 03/15/2025) and restricted stock (9,613 shares, acquired 09/15/2020). No securities were reported sold in the past three months. The filing includes the standard representation that the seller is unaware of undisclosed material adverse information about the issuer.
CME Group Inc. (CME) Form 144 notice reports a proposed sale of 32,468 shares of Common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $200,054.83 and approximate sale date of 08/18/2025. The shares were acquired as restricted stock from the issuer on 05/02/2024 and were fully paid on that date. The filing lists 360,377,042 shares outstanding. Certain fields such as the identity or relationship of the selling person and the filing contact details are not populated in the provided text. The filer represents they are not aware of undisclosed material adverse information and affirms the signature and certification language required by Form 144.
CME Group director Patrick W. Maloney reported the acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Maloney now beneficially owns 4,098 shares directly. The filing indicates this was a planned acquisition under the company's director compensation program rather than an open market purchase.
- Transaction Code: A (Grant/Award)
- Ownership Form: Direct (D)
- Filing Type: Form 4 (Statement of Changes in Beneficial Ownership)
- Total Transaction Value: $145,251.96
CME Group director Harold Eugene Ford Jr. reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Ford's direct beneficial ownership increased to 2,091 shares. The Form 4 filing indicates this was a standard director compensation grant, demonstrating ongoing alignment between board member and shareholder interests.
- Transaction Type: Stock Award (Code A)
- Role: Director (Non-Employee)
- Filing Type: Individual
- Ownership: Direct
CME Group director Elizabeth A. Cook reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 532 shares of Class A Common Stock at a price of $273.03 per share through a trust, granted pursuant to the CME Group Director Stock Plan.
Following the transaction, Cook's beneficial ownership includes:
- 18,771 shares held indirectly through a trust
- 20 shares held indirectly through a joint account
The Form 4 filing was signed by Jenelle Chalmers on behalf of Elizabeth A. Cook on June 26, 2025. This transaction represents a standard director compensation grant and demonstrates continued insider investment in the company.
CME Group director Timothy S. Bitsberger reported an insider transaction on Form 4 filed June 28, 2025, disclosing activity from June 25, 2025. Key details:
- Acquired 532 shares of Class A Common Stock at $273.03 per share
- Shares were granted through the CME Group Director Stock Plan
- Following the transaction, Bitsberger directly owns 11,121 shares
This transaction represents a standard director stock grant as part of CME Group's board compensation program. The filing was signed by Jenelle Chalmers on behalf of Bitsberger on June 26, 2025. No derivative securities were involved in this transaction.
CME Group director Rahael Seifu reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted through the CME Group Director Stock Plan.
Following this transaction, Seifu now beneficially owns 4,094 shares directly. The filing indicates this was a planned compensation grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Plan-Based)
- Ownership Type: Direct
- Role: Director
- Total Transaction Value: $145,251.96
CME Group director Patrick J. Mulchrone reported insider trading activity on June 25, 2025. Key details of the transaction include:
- Acquired 532 shares of Class A Common Stock at $273.03 per share through the CME Group Director Stock Plan
- Following the transaction, Mulchrone directly owns 28,485 shares
- Additionally holds 25,000 shares indirectly through spouse
The Form 4 filing indicates this was a planned acquisition under the company's director compensation program rather than an open market transaction. The filing was submitted by Jenelle Chalmers on behalf of Mulchrone on June 26, 2025, within the required reporting timeframe.
CME Group director Phyllis M. Lockett reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Lockett now beneficially owns 3,640 shares directly. The filing indicates this was a planned stock grant as part of director compensation rather than an open market purchase.
- Transaction Code: A (Grant/Award)
- Ownership Form: Direct (D)
- Filing Type: Form 4 (Statement of Changes in Beneficial Ownership)
- Total Transaction Value: Approximately $145,252
This insider transaction represents routine director compensation and does not indicate any unusual trading patterns or significant changes in ownership structure.